Caspase inhibition in liver transplantation: from basic research to clinical studies  by Cursio, Raffaele
LEADING ARTICLE
Caspase inhibition in liver transplantation: from basic research to
clinical studieshpb_123 1..3
Raffaele Cursio
Laboratoire de Recherches Chirurgicales, Service de Chirurgie Digestive et Transplantation Hépatique Hôpital l'Archet 2, and INSERM U895 Equipe 2 C3M,
IFR 50, Université de Nice Sophia Antipolis, Nice, France
Correspondence
Raffaele Cursio, Service de Chirurgie Digestive et Transplantation Hépatique, Hôpital l'Archet 2, 151,
route Saint Antoine de Ginestière, BP 3049, 06202 Nice Cedex 2, France. Tel: +33-4-92-03-64-76/
4-92-03-63-81; Fax: +33-4-92-03-65-62; E-mail: cursio@unice.fr
During transplantation, the liver is subjected to ischaemia and
reperfusion (I-R) injury at three distinct stages. The first, when
the liver is explanted from the donor and stored on ice at 0° to
4°C, is a variable but generally long period of cold ischaemia. The
time of anastomosis, when the liver is removed from ice until its
implantation in the recipient, represents the second, relatively
shorter stage of I-R injury. In this period of ischaemia, the liver
warms slowly up towards body temperature at a rate of 0.5°C per
minute. Normothermic reperfusion of the implanted liver with
the recipient’s blood at 37°C delineates the third stage. This cold
ischemia/normothermic reperfusion injury causes up to 10% of
early liver transplant failures and can lead to initial poor graft
function (IPGF), acute and chronic rejection.1 The pathogenesis
of cold ischaemia/normothermic reperfusion injury represents
a complex interplay between biochemical, cellular, endothelial
and tissue specific factors, with inflammation being a common
feature.
Liver cells seem to die mainly by necrosis. While cold storage
appears to cause injury predominantly to non-parenchymal cells
(Kupffer, sinusoidal endothelial and stellate cells), normothermic
ischaemia injury affects above all parenchymal cells such as hepa-
tocytes.2 The complement system plays an important role in the
development of cold ischaemia/normothermic reperfusion injury
as a manifestation on innate immunity. During cold storage,
complement fragment 4d deposition and neutrophil infiltration
were found in lobar and periportal necrotic hepatocytes resulting
in IPGF of the liver after transplantation.3
However, liver cell death during cold ischaemia/normothermic
reperfusion is not only the result of necrosis but, also of apoptosis
or programmed cell death.4 These different mechanisms of cell
death occur simultaneously during cold ischaemia, and they even
imbricate during reperfusion. Necrosis and apoptosis are interde-
pendent phenomena resulting from activation of shared pathways
and signals.5
The apoptotic process is executed actively by cysteinyl-
aspartate-specific proteases, the caspases, and occurs in a pro-
grammed fashion.6 Synthesized as inactive precursors, caspases
are activated upon specific cleavage at defined aspartate residues.
Caspase activation can be triggered by an extrinsic molecular
pathwaymediated by death receptors (Fas, TNFR1 and TRAIL) on
the cell surface and by an intrinsic molecular pathway, induced at
the mitochondrial level.6 In this apoptotic process, the ‘initiator’
caspases-8, -9 and -10 cleave and activate ‘executioner’ caspases,
mainly caspase-3, -6 and -7. The caspase activation results in
morphological cellular changes such as shrinkage of the cell, con-
densation of chromatin and disintegration of the cell into small
apoptotic bodies. Finally, these apoptotic bodies are phagocytosed
mainly by Kupffer cells without inflammatory reaction. Therefore,
the caspase pathway plays an important role in clearing apoptotic
dead cells in a way that allows remodelling of the liver cell plates
without inflammation. However, this tissue remodelling is depen-
dent not only on the degree of mitosis and apoptosis but, also on
the balance between cell death and cell clearance and a mismatch
between the execution phase of apoptosis and cell disposal may
contribute to cold/normothermic reperfusion injury of the liver.
In liver transplantation, the extent of liver injury seems to be
mirrored by caspase activity. Indeed, a set of genes involved in the
regulation of apoptosis were highly expressed in transplanted
livers of patients with IPGF.7 In these livers, an increase in
caspase-3 activity was also detected.7 During transplantation, the
initial liver graft damage occurs during cold preservation, but at
the time of reperfusion, the rapid metabolism of accumulated
metabolic products leads to the production of toxic molecules,
for example free radicals, and to the activation of apoptosis.
Ischaemia by itself can trigger apoptosis, but reperfusion acceler-
ates the process. Using fluorescence microscopy, caspase activity
has been identified particularly in cells localized in the perivascu-
lar areas of the reperfused liver.8
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Pharmacological intervention applied before and/or at the
onset of reperfusion can reduce cell death. Several animal studies
have been performed to test a variety of inhibitors targeting
caspase-mediated liver cell apoptosis. Initial studies9 examined the
effects of a pan-caspase inhibitor Z-Asp-2,3-dichlorobenzoyl-
oxymethylketone (Z-Asp-cmk), in a rat normothermic liver I-R
model. Treatment with Z-Asp-cmk was associated with lower
aminotransferase serum levels, reduced caspase-3 activity,
reduced apoptosis and improved survival. These experimental
data have paved the way for testing several caspase inhibitors in
animals to reduce liver apoptosis and consequently liver I-R injury
during liver transplantation.10,11 For example, IDN-6556, a novel
irreversible broad-spectrum caspase inhibitor, has been shown to
reduce cold ischaemia/normothermic reperfusion-induced apop-
tosis and injury of the liver.10,11 Collectively these studies have
provided solid preclinical evidence that the inhibition of liver cell
apoptosis attenuates cold ischaemia/normothermic reperfusion
injury and potentially improves the quality of liver grafts.
However, inhibition of the caspase pathwaymay be detrimental by
blocking non-inflammatory apoptotic cell clearance and thereby
promoting inflammation. The use of the pan-caspase inhibitor
z-VAD-fmk may induce macrophage overexpression and secre-
tion of several chemokines and cytokines, including TNFa, which
results in tissue inflammation prior to the death of these mac-
rophages by necrosis.12 Furthermore, when apoptotic cell death
is blocked by z-VAD-fmk, some cells will undergo an alternate
form of cell death that has distinctive characteristics and is called
necroptosis, a form of programmed cell death with characteris-
tics of necrosis.13 Finally the same pan-caspase inhibitor, by
blocking caspase activation, may induce autophagic cell death
(self-digestion).14
As caspases seem to be key mediators of apoptosis, immune
response, complement activation and inflammation pathways,
inhibiting one of these pathways individually is probably not
sufficient to prevent liver damage after cold ischaemia/
normothermic reperfusion. In contrast, blockade of caspases,
which represent the point of convergence of these different path-
ways, could offer an interesting strategy for ameliorating liver
injury, via modulation of inflammation, immune response and
apoptosis.15
A phase I clinical trial of the pan-caspase inhibitor IDN-6556
administered to patients with hepatic impairment showed that the
drug was well tolerated and contributed to a marked reduction in
serum aminotransferase levels16. These results were confirmed by
a recent study in which oral IDN-6556 lowered aminotransferase
serum activity in patients with chronic hepatitis C.17 In clinical
practice, administration of drugs could be easily performed
during graft preservation before its implantation in the recipient
and/or before graft revascularization and reperfusion. Pan-
caspase inibitor IDN-6556 has a short half-life (1-h half-life) and
this is very important, because long-term antiapoptotic effects
may have unintended consequences.11 Adding the drug to the
standard preservation solution seems ideal because the time of
exposure is limited and the substance is likewise washed out prior
to revascularization. Since then, the pan-caspase inhibitor IDN-
6556 was successfully tested in a Phase II clinical trial in human
liver transplantation.18 The IDN-6556 was administered in cold
storage and flush solutions during liver transplantation and
provided local therapeutic protection against cold ischaemia/
normothermic reperfusion-mediated apoptosis and injury. There
was no delayed graft function, no primary non-function and no
retransplantation. So, despite the limited number of patients in
this study, a further step seems to have been achieved in liver graft
protection by caspase inhibitors.18
The improved knowledge of apoptotic mechanisms during cold
ischaemia/normothermic reperfusion injury and the possibility to
inhibit the activation of the caspases involved in this type of injury
by caspase inhibitors derived from animal studies and its transla-
tion to clinical trials highlights the need and the importance of
basic research in liver transplantation.
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